Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials

Gallois, Claire
Shi, Qian
Meyers, Jeffrey P
Iveson, Timothy
Alberts, Steven R
de Gramont, Aimery
Sobrero, Alberto F
Haller, Daniel G
Oki, Eiji
Shields, Anthony Frank
Goldberg, Richard M
Kerr, Rachel
Lonardi, Sara
Yothers, Greg
Kelly, Caroline
Boukovinas, Ioannis
Labianca, Roberto
Sinicrope, Frank A
Souglakos, Ioannis
Yoshino, Takayuki
Meyerhardt, Jeffrey A
André, Thierry
Papamichael, Demetris
Taieb, Julien

October 2022

Purpose: Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for ...

Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer

Sanoff, Hanna K.
Carpenter, William R.
Martin, Christopher F.
Sargent, Daniel J.
Meyerhardt, Jeffrey A.
Stürmer, Til
Fine, Jason P.
Weeks, Jane
Niland, Joyce
Kahn, Katherine L.
Schymura, Maria J.
Schrag, Deborah

January 2012

The addition of oxaliplatin to adjuvant 5-fluorouracil (5-FU) improves survival of patients with sta...

\u201cBiweekly oxaliplatin plus irinotecan and folinic acid-modulated 5- fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer\u201d

Pcomella, B.
Palmeri, S.
Cpotzu,
V., D.
Fizzo, F.
Rcasaretti, C.

January 2006

Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxi...

Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

Sanoff, Hanna K.
Sargent, Daniel J.
Campbell, Megan E.
Morton, Roscoe F.
Fuchs, Charles S.
Ramanathan, Ramesh K.
Williamson, Stephen K.
Findlay, Brian P.
Pitot, Henry C.
Goldberg, Richard M.

January 2008

In this report, we update survival (OS) and time-to-progression (TTP) data for the Intergroup trial ...

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial

Comella, P
Massidda, B
Filippelli, G
Palmeri, S
Natale, D
Farris, A
De Vita, F
Buzzi, F
Tafuto, S
Maiorino, L
Mancarella, S
Leo, S
Lorusso, V
De Lucia, L
ROSELLI, MARIO

June 2005

The primary end point of this phase III trial was to compare the response rate (RR) of oxaliplatin (...

Original article Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741

T. Delaunoit
S. R. Alberts
D. J. Sargent
E. Green
R. M. Goldberg
J. Krook
C. Fuchs
R. K. Ramanathan
S. K. Williamson
R. F. Morton
B. P. Findlay

January 2004

Background: Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progr...

The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.

Lelli G
Carandina I
Urbini B
Guarino S
Modonesi C
Pedriali M.

January 2007

The effectiveness of oxaliplatin and irinotecan in advanced colorectal cancer therapy has been shown...

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

Seium, Y.
Stupp, R.
Ruhstaller, T.
Gervaz, P.
Mentha, G.
Philippe, M.
Allal, A.
Trembleau, C.
Bauer, J.
Morant, R.
Roth, A. D.

May 2005

BACKGROUND: A phase I-II multicenter trial was conducted to define the maximal tolerated dose and de...

\u201cOxaliplatin plus high dose folinic acid and 5-fluoruracil i.v. bolus (OXAFAFU) versus irinotecan plus high dose folinic acid and 5-fluoruracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group trial 0103\u201d

Pasquale, C.
Bruno, M.
Gianfranco, F.
Palmeri, S.
Donato, N.
Antonio, F.
FERNANDO DE, V.
Franco, B.
Salvatore, T.
Luigi, M.
Sergio, M.
Silvana, L.
Vito, L.
LUIGI DE, L.
Mario, R.

January 2005

PURPOSE: The primary end point of this phase III trial was to compare the response rate (RR) of oxa...

Will the Addition of Oxaliplatin to 5-Fluorouracil (5FU), and Leucovorin Improve Disease Free Survival of Patients With Stage III Colon Cancer Who Had Surgical Resection of the Tumor?

Cotter, Sarah

January 2015

Objective: The objective of this selective EBM review is to determine whether or not the addition of...

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial

백순명

January 2016

IMPORTANCE: Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer...

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist. 2011;16(9):1228–38.42. Brookmeyer R, Crowley J. A Confidence Interval for the Median S

Benoist Chibaudel
B Franck Bonnetain
D Christophe Tournigand
Leila Bengrine-lefevre
A Luis Teixeira
A Pascal Artru
Annette K. Larsen
E Thierry André
E Christophe Louvet
G Aimery De Gramonta

September 2016

and sanofi-aventis; and research funding from Amgen, Bayer, Genentech, sanofi-aventis, and Enzon. Se...

Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Koca, Dogan
Turhal, Nazim Serdal
Zengin, Nurullah
Uncu, Dogan
Aksoy, Sercan
Cetin, Bulent
Yetisyigit, Tarkan
Ozdemir, Nuriye
Sevinc, Alper
Karaca, Halit
ÖZKAN, Metin
Budakoglu, Burcin
HARPUTLUOĞLU, HAKAN
Inal, Ali
Dane, Faysal
Berk, Veli
Isikdogan, Abdurrahman
Ozturk, Mehmet Akif
Durnali, Ayse Gok
Cihan, Sener
Buyukberber, Suleyman
Benekli, Mustafa
Kos, Tugba
Alkis, Necati

January 2013

Objective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxal...

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

Cunningham, D
Sirohi, B
Pluzanska, A
Utracka-Hutka, B
Zaluski, J
Glynne-Jones, R
Koralewski, P
Bridgewater, J
Mainwaring, P
Wasan, H
Wang, JY
Szczylik, C
Clingan, P
Chan, RTT
Tabah-Fisch, I
Cassidy, J

February 2009

Background: Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatmen...

Level of evidence of irinotecan clinical trials and recent data in colorectal cancer

Köhne, C.-H.

June 2004

AbstractCombination chemotherapy based on bolus or infusional 5-fluorouracil (5-FU), folinic acid (F...

Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials

Gallois, Claire
Shi, Qian
Meyers, Jeffrey P
Iveson, Timothy
Alberts, Steven R
de Gramont, Aimery
Sobrero, Alberto F
Haller, Daniel G
Oki, Eiji
Shields, Anthony Frank
Goldberg, Richard M
Kerr, Rachel
Lonardi, Sara
Yothers, Greg
Kelly, Caroline
Boukovinas, Ioannis
Labianca, Roberto
Sinicrope, Frank A
Souglakos, Ioannis
Yoshino, Takayuki
Meyerhardt, Jeffrey A
André, Thierry
Papamichael, Demetris
Taieb, Julien

October 2022

Purpose: Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for ...

Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer

Sanoff, Hanna K.
Carpenter, William R.
Martin, Christopher F.
Sargent, Daniel J.
Meyerhardt, Jeffrey A.
Stürmer, Til
Fine, Jason P.
Weeks, Jane
Niland, Joyce
Kahn, Katherine L.
Schymura, Maria J.
Schrag, Deborah

January 2012

The addition of oxaliplatin to adjuvant 5-fluorouracil (5-FU) improves survival of patients with sta...

\u201cBiweekly oxaliplatin plus irinotecan and folinic acid-modulated 5- fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer\u201d

Pcomella, B.
Palmeri, S.
Cpotzu,
V., D.
Fizzo, F.
Rcasaretti, C.

January 2006

Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxi...

Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

Sanoff, Hanna K.
Sargent, Daniel J.
Campbell, Megan E.
Morton, Roscoe F.
Fuchs, Charles S.
Ramanathan, Ramesh K.
Williamson, Stephen K.
Findlay, Brian P.
Pitot, Henry C.
Goldberg, Richard M.

January 2008

In this report, we update survival (OS) and time-to-progression (TTP) data for the Intergroup trial ...

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial

Comella, P
Massidda, B
Filippelli, G
Palmeri, S
Natale, D
Farris, A
De Vita, F
Buzzi, F
Tafuto, S
Maiorino, L
Mancarella, S
Leo, S
Lorusso, V
De Lucia, L
ROSELLI, MARIO

June 2005

The primary end point of this phase III trial was to compare the response rate (RR) of oxaliplatin (...

Original article Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741

T. Delaunoit
S. R. Alberts
D. J. Sargent
E. Green
R. M. Goldberg
J. Krook
C. Fuchs
R. K. Ramanathan
S. K. Williamson
R. F. Morton
B. P. Findlay

January 2004

Background: Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progr...

The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.

Lelli G
Carandina I
Urbini B
Guarino S
Modonesi C
Pedriali M.

January 2007

The effectiveness of oxaliplatin and irinotecan in advanced colorectal cancer therapy has been shown...

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

Seium, Y.
Stupp, R.
Ruhstaller, T.
Gervaz, P.
Mentha, G.
Philippe, M.
Allal, A.
Trembleau, C.
Bauer, J.
Morant, R.
Roth, A. D.

May 2005

BACKGROUND: A phase I-II multicenter trial was conducted to define the maximal tolerated dose and de...

\u201cOxaliplatin plus high dose folinic acid and 5-fluoruracil i.v. bolus (OXAFAFU) versus irinotecan plus high dose folinic acid and 5-fluoruracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group trial 0103\u201d

Pasquale, C.
Bruno, M.
Gianfranco, F.
Palmeri, S.
Donato, N.
Antonio, F.
FERNANDO DE, V.
Franco, B.
Salvatore, T.
Luigi, M.
Sergio, M.
Silvana, L.
Vito, L.
LUIGI DE, L.
Mario, R.

January 2005

PURPOSE: The primary end point of this phase III trial was to compare the response rate (RR) of oxa...

Will the Addition of Oxaliplatin to 5-Fluorouracil (5FU), and Leucovorin Improve Disease Free Survival of Patients With Stage III Colon Cancer Who Had Surgical Resection of the Tumor?

Cotter, Sarah

January 2015

Objective: The objective of this selective EBM review is to determine whether or not the addition of...

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial

백순명

January 2016

IMPORTANCE: Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer...

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist. 2011;16(9):1228–38.42. Brookmeyer R, Crowley J. A Confidence Interval for the Median S

Benoist Chibaudel
B Franck Bonnetain
D Christophe Tournigand
Leila Bengrine-lefevre
A Luis Teixeira
A Pascal Artru
Annette K. Larsen
E Thierry André
E Christophe Louvet
G Aimery De Gramonta

September 2016

and sanofi-aventis; and research funding from Amgen, Bayer, Genentech, sanofi-aventis, and Enzon. Se...

Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Koca, Dogan
Turhal, Nazim Serdal
Zengin, Nurullah
Uncu, Dogan
Aksoy, Sercan
Cetin, Bulent
Yetisyigit, Tarkan
Ozdemir, Nuriye
Sevinc, Alper
Karaca, Halit
ÖZKAN, Metin
Budakoglu, Burcin
HARPUTLUOĞLU, HAKAN
Inal, Ali
Dane, Faysal
Berk, Veli
Isikdogan, Abdurrahman
Ozturk, Mehmet Akif
Durnali, Ayse Gok
Cihan, Sener
Buyukberber, Suleyman
Benekli, Mustafa
Kos, Tugba
Alkis, Necati

January 2013

Objective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxal...

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

Cunningham, D
Sirohi, B
Pluzanska, A
Utracka-Hutka, B
Zaluski, J
Glynne-Jones, R
Koralewski, P
Bridgewater, J
Mainwaring, P
Wasan, H
Wang, JY
Szczylik, C
Clingan, P
Chan, RTT
Tabah-Fisch, I
Cassidy, J

February 2009

Background: Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatmen...

Level of evidence of irinotecan clinical trials and recent data in colorectal cancer

Köhne, C.-H.

June 2004

AbstractCombination chemotherapy based on bolus or infusional 5-fluorouracil (5-FU), folinic acid (F...

Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials

Gallois, Claire
Shi, Qian
Meyers, Jeffrey P
Iveson, Timothy
Alberts, Steven R
de Gramont, Aimery
Sobrero, Alberto F
Haller, Daniel G
Oki, Eiji
Shields, Anthony Frank
Goldberg, Richard M
Kerr, Rachel
Lonardi, Sara
Yothers, Greg
Kelly, Caroline
Boukovinas, Ioannis
Labianca, Roberto
Sinicrope, Frank A
Souglakos, Ioannis
Yoshino, Takayuki
Meyerhardt, Jeffrey A
André, Thierry
Papamichael, Demetris
Taieb, Julien

October 2022

Purpose: Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for ...

Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer

Sanoff, Hanna K.
Carpenter, William R.
Martin, Christopher F.
Sargent, Daniel J.
Meyerhardt, Jeffrey A.
Stürmer, Til
Fine, Jason P.
Weeks, Jane
Niland, Joyce
Kahn, Katherine L.
Schymura, Maria J.
Schrag, Deborah

January 2012

The addition of oxaliplatin to adjuvant 5-fluorouracil (5-FU) improves survival of patients with sta...

\u201cBiweekly oxaliplatin plus irinotecan and folinic acid-modulated 5- fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer\u201d

Pcomella, B.
Palmeri, S.
Cpotzu,
V., D.
Fizzo, F.
Rcasaretti, C.

January 2006

Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxi...

Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

Abstract

Extracted data

Related items

Related items